GlassScriptPhysician profile
Biana Miller
NPI 1285805077
$5,924.92
in general payments reported to CMS, 2019-2025
34 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920 · 2022: $820 · 2023: $1,312 · 2024: $1,331 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,184.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,901.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,033.57 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $569.24 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $345.65 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $284.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $231.49 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.56 | 2021-2025 | Jardiance |
| Amgen INC. | $132.35 | 2021-2024 | Evenity, Prolia, Repatha |
| Currax Pharmaceuticals LLC | $95.64 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $92.06 | 2024-2025 | Rexulti |
| Seqirus USA INC | $90.86 | 2023-2024 | Fluad, Flucelvax, Fluad Quadrivalent |
| Merck Sharp & Dohme LLC | $84.32 | 2021-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Novartis Pharmaceuticals Corporation | $81.51 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $81.07 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $77.28 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $75.78 | 2021 | |
| Pfizer INC. | $73.08 | 2023-2024 | |
| Abbott Laboratories | $58.06 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $57.85 | 2022 | |
| Renalytix Ai, INC. | $54.79 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $48.53 | 2024-2025 | Veozah |
| Sanofi Pasteur INC. | $38.90 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.86 | 2022-2023 | |
| Edwards Lifesciences Corporation | $35.80 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $29.21 | 2025 | Neffy |
| Axsome Therapeutics, INC. | $27.35 | 2025 | Auvelity |
| Intra-Sana Laboratories | $23.48 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| E.R. Squibb & Sons, L.L.C. | $21.19 | 2022 | |
| Sumitomo Pharma America, INC. | $20.45 | 2025 | Gemtesa |
| Kaleo, INC. | $18.32 | 2021 | |
| Ibsa Pharma INC. | $17.33 | 2025 | Flector, Licart, Tirosint |
| Idorsia Pharmaceuticals US INC | $16.64 | 2022 | |
| Lundbeck LLC | $16.55 | 2024 | Rexulti |
| Alexion Pharmaceuticals, INC. | $16.22 | 2023 | Koselugo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biana Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.